Meige's syndrome in a patient treated with ranitidine
Identifieur interne : 002E70 ( PascalFrancis/Corpus ); précédent : 002E69; suivant : 002E71Meige's syndrome in a patient treated with ranitidine
Auteurs : F. Le Doze ; M. Moulin ; G.-L. DeferSource :
- Movement disorders [ 0885-3185 ] ; 1999.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 99-0086358 INIST |
---|---|
ET : | Meige's syndrome in a patient treated with ranitidine |
AU : | LE DOZE (F.); MOULIN (M.); DEFER (G.-L.) |
AF : | Department of Neurology Dejerine, Centre Régional de Pharmacovigilance de Basse-Normandie, Department of Pharmacology, CHU Caen/France (1 aut.); Centre Régional de Pharmacovigilance de Basse-Normandie, Department of Pharmacology, CHU Caen/France (2 aut.); Department of Neurology Dejerine, CHU Caen/France (3 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1999; Vol. 14; No. 1; Pp. 175-177; Bibl. 19 ref. |
LA : | Anglais |
CC : | 002B02U01 |
FD : | Dyskinésie buccofaciale; Meige syndrome; Transitoire; Blépharospasme; Ranitidine; Chimiothérapie; Antiulcéreux; Antagoniste; Récepteur histaminergique H2; Ulcère; Pylore; Toxicité; Traitement; Etude cas; Personne âgée; Femelle |
FG : | Homme; Système nerveux pathologie; Trouble neurologique; Mouvement involontaire; Extrapyramidal syndrome; Oeil pathologie; Paupière pathologie; Appareil digestif pathologie; Estomac pathologie |
ED : | Buccofacial dyskinesia; Meige syndrome; Transitory; Blepharospasm; Ranitidine; Chemotherapy; Antiulcer agent; Antagonist; H2 Histamine receptor; Ulcer; Pylorus; Toxicity; Treatment; Case study; Elderly; Female |
EG : | Human; Nervous system diseases; Neurological disorder; Involuntary movement; Extrapyramidal syndrome; Eye disease; Eyelid disease; Digestive diseases; Gastric disease |
GD : | Giftigkeit; Aufbereiten |
SD : | Disquinesia bucofacial; Meige síndrome; Transitorio; Blefaroespasmo; Ranitidina; Quimioterapia; Antiulceroso; Antagonista; Receptor histaminérgico H2; Ulcera; Píloro; Toxicidad; Tratamiento; Estudio caso; Anciano; Hembra |
LO : | INIST-20953.354000073349160330 |
ID : | 99-0086358 |
Links to Exploration step
Pascal:99-0086358Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Meige's syndrome in a patient treated with ranitidine</title>
<author><name sortKey="Le Doze, F" sort="Le Doze, F" uniqKey="Le Doze F" first="F." last="Le Doze">F. Le Doze</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology Dejerine, Centre Régional de Pharmacovigilance de Basse-Normandie, Department of Pharmacology, CHU Caen</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Moulin, M" sort="Moulin, M" uniqKey="Moulin M" first="M." last="Moulin">M. Moulin</name>
<affiliation><inist:fA14 i1="02"><s1>Centre Régional de Pharmacovigilance de Basse-Normandie, Department of Pharmacology, CHU Caen</s1>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Defer, G L" sort="Defer, G L" uniqKey="Defer G" first="G.-L." last="Defer">G.-L. Defer</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology Dejerine, CHU Caen</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0086358</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0086358 INIST</idno>
<idno type="RBID">Pascal:99-0086358</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002E70</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Meige's syndrome in a patient treated with ranitidine</title>
<author><name sortKey="Le Doze, F" sort="Le Doze, F" uniqKey="Le Doze F" first="F." last="Le Doze">F. Le Doze</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology Dejerine, Centre Régional de Pharmacovigilance de Basse-Normandie, Department of Pharmacology, CHU Caen</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Moulin, M" sort="Moulin, M" uniqKey="Moulin M" first="M." last="Moulin">M. Moulin</name>
<affiliation><inist:fA14 i1="02"><s1>Centre Régional de Pharmacovigilance de Basse-Normandie, Department of Pharmacology, CHU Caen</s1>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Defer, G L" sort="Defer, G L" uniqKey="Defer G" first="G.-L." last="Defer">G.-L. Defer</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology Dejerine, CHU Caen</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antagonist</term>
<term>Antiulcer agent</term>
<term>Blepharospasm</term>
<term>Buccofacial dyskinesia</term>
<term>Case study</term>
<term>Chemotherapy</term>
<term>Elderly</term>
<term>Female</term>
<term>H2 Histamine receptor</term>
<term>Meige syndrome</term>
<term>Pylorus</term>
<term>Ranitidine</term>
<term>Toxicity</term>
<term>Transitory</term>
<term>Treatment</term>
<term>Ulcer</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie buccofaciale</term>
<term>Meige syndrome</term>
<term>Transitoire</term>
<term>Blépharospasme</term>
<term>Ranitidine</term>
<term>Chimiothérapie</term>
<term>Antiulcéreux</term>
<term>Antagoniste</term>
<term>Récepteur histaminergique H2</term>
<term>Ulcère</term>
<term>Pylore</term>
<term>Toxicité</term>
<term>Traitement</term>
<term>Etude cas</term>
<term>Personne âgée</term>
<term>Femelle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>14</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Meige's syndrome in a patient treated with ranitidine</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LE DOZE (F.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MOULIN (M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DEFER (G.-L.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology Dejerine, Centre Régional de Pharmacovigilance de Basse-Normandie, Department of Pharmacology, CHU Caen</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Centre Régional de Pharmacovigilance de Basse-Normandie, Department of Pharmacology, CHU Caen</s1>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology Dejerine, CHU Caen</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>175-177</s1>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000073349160330</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>19 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0086358</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dyskinésie buccofaciale</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Buccofacial dyskinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Disquinesia bucofacial</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Meige syndrome</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Meige syndrome</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Meige síndrome</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Transitoire</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Transitory</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Transitorio</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Blépharospasme</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Blepharospasm</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Blefaroespasmo</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Ranitidine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Ranitidine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Ranitidina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Antiulcéreux</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Antiulcer agent</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Antiulceroso</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Antagoniste</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Antagonist</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Antagonista</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Récepteur histaminergique H2</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>H2 Histamine receptor</s0>
<s5>11</s5>
<s6>«H2» Histamine receptor</s6>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Receptor histaminérgico H2</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Ulcère</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Ulcer</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Ulcera</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Pylore</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Pylorus</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Píloro</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="GER"><s0>Giftigkeit</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Traitement</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Treatment</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Case study</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Personne âgée</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Elderly</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Anciano</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Femelle</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Female</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Hembra</s0>
<s5>21</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Oeil pathologie</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Eye disease</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Ojo patología</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Paupière pathologie</s0>
<s5>46</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Eyelid disease</s0>
<s5>46</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Párpado patología</s0>
<s5>46</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Appareil digestif pathologie</s0>
<s5>69</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Digestive diseases</s0>
<s5>69</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Aparato digestivo patología</s0>
<s5>69</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Estomac pathologie</s0>
<s5>70</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Gastric disease</s0>
<s5>70</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Estómago patología</s0>
<s5>70</s5>
</fC07>
<fN21><s1>046</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 99-0086358 INIST</NO>
<ET>Meige's syndrome in a patient treated with ranitidine</ET>
<AU>LE DOZE (F.); MOULIN (M.); DEFER (G.-L.)</AU>
<AF>Department of Neurology Dejerine, Centre Régional de Pharmacovigilance de Basse-Normandie, Department of Pharmacology, CHU Caen/France (1 aut.); Centre Régional de Pharmacovigilance de Basse-Normandie, Department of Pharmacology, CHU Caen/France (2 aut.); Department of Neurology Dejerine, CHU Caen/France (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1999; Vol. 14; No. 1; Pp. 175-177; Bibl. 19 ref.</SO>
<LA>Anglais</LA>
<CC>002B02U01</CC>
<FD>Dyskinésie buccofaciale; Meige syndrome; Transitoire; Blépharospasme; Ranitidine; Chimiothérapie; Antiulcéreux; Antagoniste; Récepteur histaminergique H2; Ulcère; Pylore; Toxicité; Traitement; Etude cas; Personne âgée; Femelle</FD>
<FG>Homme; Système nerveux pathologie; Trouble neurologique; Mouvement involontaire; Extrapyramidal syndrome; Oeil pathologie; Paupière pathologie; Appareil digestif pathologie; Estomac pathologie</FG>
<ED>Buccofacial dyskinesia; Meige syndrome; Transitory; Blepharospasm; Ranitidine; Chemotherapy; Antiulcer agent; Antagonist; H2 Histamine receptor; Ulcer; Pylorus; Toxicity; Treatment; Case study; Elderly; Female</ED>
<EG>Human; Nervous system diseases; Neurological disorder; Involuntary movement; Extrapyramidal syndrome; Eye disease; Eyelid disease; Digestive diseases; Gastric disease</EG>
<GD>Giftigkeit; Aufbereiten</GD>
<SD>Disquinesia bucofacial; Meige síndrome; Transitorio; Blefaroespasmo; Ranitidina; Quimioterapia; Antiulceroso; Antagonista; Receptor histaminérgico H2; Ulcera; Píloro; Toxicidad; Tratamiento; Estudio caso; Anciano; Hembra</SD>
<LO>INIST-20953.354000073349160330</LO>
<ID>99-0086358</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E70 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002E70 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:99-0086358 |texte= Meige's syndrome in a patient treated with ranitidine }}
This area was generated with Dilib version V0.6.23. |